. The Supreme Court's landmark June 28, 2024 decision inLoper Bright Enterprises v. Raimondoabandoned theChevrondoctrine after 40 years of deferring to agency interpretations of ambiguous laws. As previewed in ourJune 28 alert,Lopercontinues the Court's departure from agency deference through this most significant blow. The practical impacts ofLoperon the robust healthcare regulatory regime will be tested in the ensuing months and years. We examine what is and is not likely to change for the healthcare industry. While the full breadth of theLoperdecision's ripple effects remains to be seen, we consider below some of the potential implications for healthcare laws, agencies, and industry stakeholders. See more . DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations. Venable LLP Attorney Advertising. Refine your interests . Back to Top. Explore 2024 Readers' Choice Awards. Copyright JD Supra, LLC
The Supreme Court's decision in Loper Bright Enterprises v. Raimondo marks the end of Chevrondoctrine and agency deference, impacting the healthcare industry. The ruling's full implications are yet to unfold, but changes in healthcare laws and stakeholders' roles are anticipated.